BFM
VIR icon

Boothbay Fund Management’s Vir Biotechnology VIR Stock Holding History

Boothbay Fund Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-259
Closed -$1.33M – 2134
2021
Q1 		$1.33M Sell
259
-20
-7% -$1.08K 0.05% 477
2020
Q4 		$747K Buy
+279
New +$9.07K 0.03% 607

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Boothbay Fund Management's VIR Position: Q2 2026 in Review

Boothbay Fund Management sold out of Vir Biotechnology (VIR) in Q2 2026, closing a stake of 63,227 shares — an estimated $567K sold.

Boothbay Fund Management first reported a position in VIR in Q2 2020 and held it in 8 quarters. The position peaked at $1.99M in Q1 2025. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Boothbay Fund Management reported no remaining Vir Biotechnology position as of Q2 2026 after selling out during the quarter.
  • Boothbay Fund Management sold 63,227 Vir Biotechnology shares in Q2 2026, an estimated $567K.
  • Boothbay Fund Management first reported a position in Vir Biotechnology in Q2 2020 and held it in 8 quarters.
  • Boothbay Fund Management's Vir Biotechnology position peaked at $1.99M in Q1 2025.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.